Diarrhea and colitis occur in 10%-35% of patients treated with anti-CTLA-4, 1%-10% with anti-PD-1, and 15-32% with anti-PD-1 and anti-CTLA-4 combination therapy (27). The gene discussed is CTLA4; the disease is colitis.